Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of medicare hemodialysis patients

American Journal of Nephrology

Volumn 34, Issue 4, 2011, Pages 298-308

  Weinhandl, Eric D ^a   Gilbertson, David T ^a   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Epoetin alfa; Erythropoiesis stimulating agent; Hemoglobin level; Mortality

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL CATHETERIZATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; MORTALITY; OUTPATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; COHORT STUDIES; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICARE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79961101743     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000330693     Document Type: Article

References (28)

1. Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590. (Pubitemid 28385655)
2. Singh AK, Szczech L, Tang KL, et al.: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098. (Pubitemid 44749317)
3. Drueke TB, Locatelli F, Clyne N, et al.: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084. (Pubitemid 44749316)
4. Pfeffer MA, Burdmann EA, Chen CY, et al.: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
5. Zhang Y, Thamer M, Stefanik K, et al.: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866-876. (Pubitemid 39445919)
6. Bradbury BD, Wang O, Critchlow CW, et al.: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008;51:62-70. (Pubitemid 350296516)
7. Szczech LA, Barnhart HX, Inrig JK, et al.: Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798.
8. Zhang Y, Thamer M, Cotter D, et al.: Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009;4:638-644.
9. Bradbury BD, Do TP, Winkelmayer WC, et al.: Greater epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dl. Pharmacoepidemiol Drug Saf 2009;18:932-940.
10. Wang O, Kilpatrick RD, Critchlow CW, et al.: Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010;5:182-188.
11. Adamson JW: Hyporesponsiveness to erythropoiesis-stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chronic Kidney Dis 2009;16:76-82.
12. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560. (Pubitemid 30660034)
13. Petersen ML, Deeks SG, Martin JN, van der Laan MJ: History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol 2007;166:985-993. (Pubitemid 47574692)
14. Nagelkerke NJD: A note on a general definition of the coefficient of determination. Biometrika 1991;78:691-692.
15. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388. (Pubitemid 46188479)
16. Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-1282.
17. Regidor DL, Kopple JD, Kovesdy CP, et al.: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
18. Robinson BM, Joffe MM, Berns JS, et al.: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005;68:2323-2330. (Pubitemid 43117811)
19. Brines M, Cerami A: Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-250. (Pubitemid 44086573)
20. Weiner DE, Miskulin DC, Seefeld K, et al.: Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007;18:3184-3191. (Pubitemid 350223979)
21. Acquavella JF, Weinhandl E, Bradbury BD, et al.: Confounding by indication studying epoetin and mortality (abstract). Pharmacoepidemiol Drug Saf 2009;18(suppl 1):S28.
22. Brookhart MA, Schneeweiss S, Avorn J, et al.: Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010;303:857-864.
23. Keown PA, Churchill DN, Poulin-Costello M, et al.: Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010;14:168-173.
24. Muirhead N, Keown PA, Churchill DN, et al.: Dialysis patients treated with epoetin α show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010 (E-pub ahead of print).
25. Tsai YC, Hung CC, Hwang SJ, et al.: Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease. Nephrol Dial Transplant 2010;25:1621-1626.
26. Ibrahim HN, Skeans, MA, Li Q, Ishani A, Snyder JJ: Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transplant (E-pub ahead of print).
27. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents -time for a reevaluation. N Engl J Med 2010;362:189-192.
28. Strippoli GF: Effects of the dose of erythropoiesis-stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11:70.